Abstract. The present study investigated the protective effects of emodin on intestinal epithelial tight junction (TJ) barrier integrity in cecal ligation and puncture (CLP)-induced septic rats and its possible mechanisms of action. Healthy male Sprague-Dawley rats were randomly divided into three groups (n=20 per group): Sham group, CLP group and CLP + emodin group. Animals were sacrificed at 12 and 24 h after the model was established. Abdominal aortic blood and specimens of the ileum were harvested for analysis. The histopathological changes in intestinal mucosa and the ultrastructures of intestinal epithelial cells were investigated using light microscopy and transmission electron microscopy. The integrity of the intestinal barrier was assessed by examining plasma diamine oxidase (DAO) levels and the ratio of urine lactulose to mannitol (L/M). The levels of the intestinal TJ proteins claudin-3, zonula occludens (ZO)-1 and occludin were detected using immunohistochemistry, western blotting and reverse transcription-quantitative PCR. The results showed that the pathological damage to intestinal mucosa and the intestinal tissue injury score in the CLP + emodin group were significantly reduced compared to those of the CLP group, and the differences were more obvious at 24 h compared with 12 h. DAO activity and the L/M ratio in the emodin pre-treatment group decreased significantly at 24 h compared with the CLP groups. The protein and mRNA levels of the TJ proteins claudin-3, ZO-1 and occludin in the emodin pre-treatment groups at 12 and 24 h were increased, while occludin mRNA level was found to be decreased compared with the CLP groups. The present study suggested that emodin may significantly reduce the damage to the intestinal epithelial barrier in sepsis, inhibit intestinal barrier permeability and protect intestinal barrier integrity. Emodin may protect intestinal barrier integrity by elevating expression levels of the TJ proteins claudin-3, ZO-1 and occludin in CLP rats.

Introduction

Sepsis is a systemic inflammatory response that is caused by an overactive host response to infection (1). Although a series of advances have been made in medical therapy for sepsis, the mortality rate remains high (2) and is a challenge that has to be regularly overcome in the clinic (3). Sepsis causes excessive tissue damage and death in approximately 30-50% of patients (4), and sepsis/septic shock are often accompanied by intestinal barrier dysfunction (5). Previous studies have revealed that intestinal barrier dysfunction plays an important role in the development of multiple organ dysfunction syndrome in sepsis (6,7). Under normal physiological conditions, the intestinal epithelial barrier can effectively prevent viral microorganisms and endotoxins from transferring from the intestinal lumen to the blood (8). When sepsis occurs, an excessive inflammatory response contributes to intestinal epithelial cell apoptosis (9). Tight junctions (TJs) between epithelial cells are disrupted and paracellular gaps are widened (10), leading to impaired intestinal mucosal integrity. Furthermore, damage to the intestinal mucosa exacerbates bacterial translocation, leading to virulence factors that further activate the host immune inflammatory defence mechanisms, eventually resulting in multiple organ failure and life-threatening clinical symptoms (11). Destruction of the intestinal barrier integrity may be an important pathway which leads to the multiple organ dysfunction caused by sepsis (12). Protecting against intestinal epithelial barrier damage and maintaining intestinal epithelial barrier integrity reduces intestinal permeability and bacterial translocation. This protection is essential to improving the prognosis and survival of patients with sepsis (13).
Rhubarb is used as a traditional Chinese medicine to treat intestinal diseases, and has been demonstrated to relieve intestinal damage in septic rats (14). Currently, a number of active ingredients have been extracted from rhubarb, including emodin, aloe-emodin, chrysophanol and physcion (15). It is not clear which of these components provides a protective effect on the intestinal mucosa in sepsis. Among them, emodin is the main effective component of rhubarb and is an anthraquione derivative extracted from the rhizome of rhubarb (16). Emodin has numerous biological effects, such as antimicrobial, anti-inflammatory, anti-viral, antibacterial, anti-tumour and anti-fibrotic activities, as well as being able to affect diastolic blood pressure (17). Ning et al (18) showed that emodin can alleviate intestinal mucosal damage in experimental severe acute pancreatitis by inhibiting inflammatory cytokines, including interleukin (IL)-1β and IL-18. Wang et al (11), found that rhubarb monomers could promote the expression of the TJ proteins claudin-5, zonula occludens (ZO)-1 and occludin and that this protected the intestinal mucosal barrier of rats with sepsis induced by cecal ligation and puncture (CLP). However, there is still no evidence showing the mechanism of action by which emodin protects the intestinal epithelial barrier integrity during sepsis. Since the integrity of the intestinal epithelial barrier is predominantly maintained by intestinal epithelial TJs, the mechanism by which the intestinal epithelial barrier can be improved has been a focus of research (19). Various TJ proteins are expressed differently in intestinal tissue. The mRNA expression levels of claudin-3 are higher in the duodenum than the distal colon, while claudin-5 shows the reverse relationship (20,21). In the present study, it was hypothesized that emodin provides a protective function on intestinal epithelial TJ barrier integrity in CLP-induced septic rats. A possible mechanism was related to the expression of the TJ proteins claudin-3, ZO-1 and occludin.

Materials and methods

Ethics approval. The present study was approved by the Ethics Committee of Putuo Hospital affiliated with Shanghai University of Traditional Chinese Medicine. Specific pathogen-free male Sprague-Dawley rats (n=60) weighing 280±20 g and aged 8-10 weeks were obtained from the Shanghai Slack Laboratory Animal Co., Ltd. All rats were acclimatized in housing conditions at 24±2˚C, 50% humidity and 12 h light-dark cycles. Rats were fed with conventional laboratory feed and water ad libitum. All animal experiments were in accordance with the Experimental Animal Centre Committee of Putuo Hospital (certification no. SYNK 2018-0032).

Animals and experimental design. Following the random number table method, rats were divided into the sham group, CLP group and CLP + emodin group, with 20 rats in each group. The CLP + emodin group was intragastrically administered with 35 mg kg⁻¹ emodin [high-performance liquid chromatography (HPLC) ≥98%; Shanghai Gefan Biotechnology Co., Ltd.] in a 0.5% sodium carboxy-methylcellulose suspension (prepared to contain emodin at 5 g L⁻¹) once daily at 09:00 a.m., for 5 days (22). The sham and CLP groups were intragastrically administered an equal amount of 0.5% sodium carboxy-methylcellulose solution. Following 2 h after the last gavage, the sepsis model was induced in the CLP and CLP + emodin groups. The sham group was treated as previously described (23), briefly: The rats were anaesthetized, and a 1 cm incision was made along the midline of the abdomen. The caecum was removed and the caecal wall was ligated using a 4/0 silk thread. A 1 cm syringe needle was used to puncture the ecum at the ligation site, a small amount of faeces was squeezed out, and the peritoneum and skin were stitched. Finally, 10 rats from each group were sacrificed at 12 h and 24 h after model establishment. Prior to sacrifice, all rats were anesthetized using an intraperitoneal injection of 2.5% sodium pentobarbital (50 mg kg⁻¹). Rats were sacrificed by cervical dislocation immediately following blood collection. The blood was collected from the abdominal aorta, and the ileum tissues were separated from the ileocecal area.

Haematoxylin and eosin (H&E) staining for histopathology. The ileum tissues were fixed with 10% formalin at room temperature for 7 days. The samples were dehydrated, embedded in paraffin, sliced into 4-µm sections and stained with H&E. Samples were stained with haematoxylin for 10 min and stained with eosin for 2 min at room temperature. Subsequently, the sections were examined under a light microscope at magnification, x400. The images were observed by two pathologists who were blinded to the experimental conditions of the present study. Intestinal mucosal injuries were assessed using Chiu's score grading (25).

Transmission electron microscopy. A small segment of the ileum was spread on filter paper to make a specimen of 1.5×1.5 cm and fixed with 2.5% glutaraldehyde at 4˚C for 7 days. Then, in conjunction with the Electron Microscopy Testing Centre of Shanghai University of Traditional Chinese Medicine, the ileum specimens were adjusted to ~1 mm³, incubated with 1% osmium acid at room temperature for 2 h, and finally dehydrated with ethanol and acetone. The fixed tissue was embedded in epoxy resin and cut into 50-nm ultrathin sections. The sections were then stained with uranyl acetate at room temperature for 2 h. The tissue sections were observed under a transmission electron microscope and images were captured at magnification, x8,200 to determine whether the microvilli arrangement on the surface of intestinal mucosal epithelial cells and the ultrastructures of organelles such as epithelial space, TJs and mitochondria in epithelial cells were normal.

Detection of diamine oxidase (DAO) activity in intestinal tissue. Blood taken from the abdominal aorta of each rat was centrifuged at 1,006.2 x g at 4˚C for 15 min. The supernatant was collected and stored at -80˚C until examination. The activity of DAO was determined using a DAO kit (Nanjing Jiancheng Bioengineering Institute). The procedure followed...
Detection of the urine lactulose/mannitol (L/M) ratio in intestinal tissue. The rats were given a mannitol (HPLC ≥98%; Shanghai Gefan Biotechnology Co., Ltd.) and lactulose (HPLC ≥98%; Shanghai Gefan Biotechnology Co., Ltd.) suspension [50 mg mannitol and 100 mg lactulose dissolved in 2 ml double distilled (dd)H2O], administered intragastrically 2 ml/rat, 2 h after establishing the sepsis model. Urine was collected within 6 h and was centrifuged at 8,049.6 x g at 4°C for 4 min. The supernatant was stored at -80°C and analyzed by mass spectrometry in collaboration with the Shanghai University of Traditional Chinese Medicine Science and Technology Innovation Centre. Standards were prepared by diluting mannitol, lactulose and deuterated mannitol with ddH2O to varying concentrations. The samples were diluted 10 times with ddH2O; then, 50 µl of sample was added to 450 µl of acetonitrile (containing 1 µg ml⁻¹ internal standard), vortexed at room temperature for 1 min, and centrifuged at 14,310.4 x g at 4°C for 5 min. A total of 10 µl of the supernatant was sampled. The instrument parameters were set, including the mass spectrometry conditions. Electrospray ion source nozzle position was 3.7, atomizing gas flow rate was 10 l min⁻¹, gas curtain gas flow rate was 12 l min⁻¹, collision gas flow rate was 12 l min⁻¹, ion source voltage was -4500 V, ion source temperature was 300°C, and ion selective channel m/z (mass to charge ratio) were as follows: Lactulose, 341.1/160.7 (collision energy, -13; declustering potential, -74); mannitol, 181.1/88.9 (collision energy, -21; declustering potential, -70); and deuterated mannitol, 183.0/88.9 (collision energy, -21; declustering potential, -67). Isocratic elution at a flow rate of 0.3 ml min⁻¹ and a volume of 10 µl per sample were used. The chromatogram was recorded and the sample content was calculated from the standard curve. Finally, the urine L/M ratio and statistics were calculated.

Immunohistochemistry. Ileum tissue was fixed in 10% formalin at room temperature for 7 days. The tissue pieces were cut and embedded in paraffin. Sections were cut to a thickness into 5-µm and placed on slides. The samples were dehydrated by gradient alcohol. The alcohol concentration was 100, 95, 90, 80, 70, 50, and 30%, and dehydration was performed for ~35 min at room temperature. A 1% sodium citrate antigen repair solution was used to soak the slides in a 100°C water bath for 30 min. When cooled to room temperature, the samples were incubated with 3% hydrogen peroxide for 10 min and rinsed with 1X PBS (3X5 min) before incubation with 5% BSA at 37°C for 10 min. Rabbit antibodies against ZO-1 (1:100; cat. no. 40-2200; Invitrogen; Thermo Fisher Scientific, Inc.), occludin (1:80; cat. no. ab216327; Abcam) and claudin-3 (1:80; cat. no. ab15102; Abcam) were added and incubated at 4°C overnight. The slides were washed with 1X PBS (3X5 min), and horseradish peroxidase conjugated anti-rabbit immunoglobulin G secondary antibody (cat. no. SA1022; Boster Biological Technology) was added and incubated at 37°C for 30 min. The slides were washed with 1X PBS (3X5 min), StreptAvidin-Biotin Complex was added and incubated at 37°C for 30 min. The slides were washed with 1X PBS (3X5 min), and 3,3’-diaminobenzidine dye was added at room temperature for 1-3 sec under a fluorescent microscope. The slides were washed with 1X PBS (3X5 min) and counterstained with haematoxylin at room temperature for ~15 sec. Then, the slides were dehydrated with gradient alcohol and the alcohol concentration was 30, 50, 70, 80, 90, 95 and 100%, and dehydration was performed for ~20 min at room temperature. Xylene was subsequently added to the slides at room temperature for ~10 min, glass coverslips were added and images were captured with a fluorescent microscope (magnification, x200).

Western blot analysis. Ileum tissues were removed from -80°C storage and cut into 50-µm pieces. A total of 1 ml protein lysis buffer (1:1) composed of RIPA buffer (cat. no. P0013C; Beyotime Institute of Biotechnology) and EDTA-free protease inhibitor cocktail (cat. no. 04693132001; Roche; Merck KGaA) was added to extract the proteins using a tissue homogenizer. The supernatant was then collected by centrifugation at 8,049.6 x g at 4°C for 5 min. Total protein was determined using a bicinchoninic acid protein quantitation kit (cat. no. P0010S; Beyotime Institute of Biotechnology). Samples were mixed with 1X SDS-PAGE protein loading buffer (cat. no. P0015; Beyotime Institute of Biotechnology) and denatured by heating at 100°C for 15 min. Next, the samples (60 µg protein) were separated on SDS-PAGE with 10% gel (cat. no. P0012A; Beyotime Biotechnology) until the bromophenol blue had migrated out of the end of the gel. Proteins were then transferred on to a PVDF membrane (EMD Millipore) and blocked in 5% milk at room temperature for 2 h. The membranes were incubated overnight with rabbit antibodies against GAPDH (0.925 mg/ml; 1:3,000 dilution; cat. no. ab181602; Abcam), ZO-1 (0.25 mg/ml; 1:1,000 dilution; cat. no. 40-2200; Invitrogen; Thermo Fisher Scientific, Inc.), occludin (0.604 mg/ml; 1:500 dilution; cat. no. ab216327; Abcam), and claudin-3 (500 µl, 1:1,000 dilution; cat. no. ab15102; Abcam). The membranes were washed with 1X TBST (3X10 min) and developed using the Clarity Western ECL substrate (cat. no. 111-005-003; Jackson ImmunoResearch Laboratories, Inc.) at room temperature for 2 h. The membranes were washed with 1X TBST (3X10 min) and developed using the Clarity Western ECL substrate (cat. no. 170-5060; Bio-Rad Laboratories, Inc.). Finally, the density of the bands was quantified using ImageJ software (version 1.51; National Institutes of Health). Data were normalized against a housekeeping gene GAPDH and the expression levels of the other groups were presented as the relative fold difference compared to the sham group (26).

Reverse transcription-quantitative PCR (RT-qPCR). The ileum tissues were removed from -80°C storage and cut into 50-µm pieces. Total RNA was extracted with TRIzol® reagent (cat. no. 9109; Takara Biotechnology Co., Ltd.) following the manufacturer's instructions. The concentration of the RNA samples was determined using spectrophotometric optical density measurement at 260 nm. A total of 1 µg of total RNA from each sample was reverse transcribed into cDNA using a PrimeScript RT Reagent kit (cat. no. RR047A; Takara Bio, Inc.). The following heat cycle was used for RT: 42°C for 2 min, 37°C for 15 min at and 85°C for 5 sec. PCR was performed using a microplate reader at 340 nm within 20 sec. A standard curve was used to calculate the activity of DAO and to statistically analyse the data.
using a PCR machine (Applied Biosystems; Thermo Fisher Scientific, Inc.). Each reaction volume consisted of 20 µl and contained 5 µl of sample cDNA, 10.4 µl TB Green Premix Ex Taq PCR master mix (cat. no. RR420A; Takara Bio, Inc.), 0.5 µl each of forward and reserve primers and 3.6 µl ddH2O. β-actin was used as a reference gene. The primer sequences of the target genes are shown in Table I.

The PCR conditions were 1 min at 95˚C, followed by 40 cycles of 5 sec at 95˚C and 30 sec at 60˚C. The last stage was followed by an incubation of 15 sec at 95˚C, 1 min at 60˚C and 15 sec at 95˚C to establish a PCR melting curve. Relative quantification of PCR products was normalized against the sham group to calculate the relative expression in the CLP group and CLP + emodin group. Relative expression levels of ZO-1, occludin, and claudin-3 mRNA levels were analyzed using the 2−ΔΔCq method (27) with QuantStudio_Flex Real-Time PCR System software (version 1.3; Thermo Fisher Scientific, Inc.).

Statistical analysis. All statistical analyses were performed using SPSS software (version 24.0; IBM Corp.), and the measurement data are expressed as the mean ± SD. All data were tested for homogeneity of variances. One-way ANOVAs were used for comparisons between groups. Fisher’s least significant difference test was used for multiple comparisons between groups. The pathological scores were compared using Kruskal-Wallis test with post-hoc Nemenyi tests for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

Emodin alleviates the pathological changes of intestinal epithelial TJ barrier injury in septic rats

Emodin maintains the integrity of the intestinal epithelial barrier in sepsis by reducing serum DAO levels. The plasma DAO results (Fig. 3A) indicated that compared with the corresponding sham groups, the DAO levels in the CLP groups increased significantly (P<0.05; 12 and 24 h, respectively) and peaked at 24 h. After emodin intervention, the activity of DAO was significantly lower in the CLP + emodin treatment group when compared with that of the corresponding CLP groups at 12 and 24 h (P<0.05; 12 and 24 h, respectively). The above data indicated that emodin could inhibit the increase in DAO activity in the serum of rats with CLP-induced sepsis and had a protective effect in intestinal mucosal injury.

Emodin maintains the integrity of the intestinal epithelial barrier in sepsis by reducing the L/M ratio in urine. The results of high-performance liquid chromatography-based
mass spectrometry for the determination of mannitol and lactulose in urine (Fig. 3B) showed that the urine L/M ratio in the sham group did not change significantly with time. In the CLP group, the L/M ratio was significantly increased compared with that of the sham group (P<0.01; 12 and 24 h, respectively). Compared with the L/M ratio in the CLP group, the L/M ratio in the CLP + emodin group was significantly reduced at 24 h (P<0.05; 24 h). These data suggested that emodin could inhibit the increase in intestinal epithelial barrier permeability in septic rats and help to maintain the integrity of the epithelial barrier.

Figure 1. Histological assessment of the effects of emodin on intestinal tissue of CLP-induced septic rats. Representative images of hematoxylin and eosin-stained intestinal sections at 12 and 24 h after CLP operation for (A) the sham group, (B) the CLP group and (C) the CLP + emodin group. (D) Intestinal tissue Chiu’s scores are shown. The intestinal mucosa of the CLP group (red dotted box) had severe congestion, oedema, inflammatory cell infiltration and widened intestinal villus. Further enlargement or shedding of intestinal epithelial space were evident along with a high Chiu’s score compared with those of the sham group. Emodin had a therapeutic effect in the CLP + emodin group. The data are presented as the mean ± standard deviation. **P<0.01 vs. the corresponding CLP group; ΔΔP<0.01 vs. the corresponding sham group. Magnification, x400. CLP, cecal ligation and puncture.

Emodin promotes the expression of the TJ protein claudin-3 in the intestinal epithelium of CLP-induced septic rats. As shown in Fig. 4, immunohistochemical microscopy images showed the expression of claudin-3 in the ileums of septic rats (Fig. 4A). In the sham group, claudin-3 expression (brown) was uniformly distributed in the intestinal epithelial cells at the apex of each connection and it was tightly packed with smooth edges. Claudin-3 was unevenly distributed, with rough edges and faded staining in the CLP group. However, in the CLP + emodin group, claudin-3 staining was darker and continuously distributed. Western blotting (Fig. 4D) and RT-qPCR analysis (Fig. 4E) showed that compared with the expression levels in the sham group, the expression of claudin-3 was decreased in the CLP group, and there was a significant difference at 24 h (P<0.01 in the western blotting and RT-qPCR, respectively). With the emodin intervention, claudin-3 protein levels were significantly increased in the emodin pre-treatment groups at 12 and 24 h compared to the CLP treatment alone (P<0.01 and P<0.05; 12 and 24 h, respectively). The trend in claudin-3 mRNA levels was consistent with that of the protein levels (P<0.05 and P<0.01; 12 and 24 h, respectively). These data indicated that emodin could inhibit the increase in intestinal barrier permeability in sepsis by promoting the expression of claudin-3 protein and mRNA.

Emodin promotes the expression of the TJ protein ZO-1 in the intestinal epithelium of CLP-induced septic rats. As depicted in Fig. 4, immunohistochemical microscopy images showed ZO-1 expression in the ileums of septic rats (Fig. 4B). In the sham group, ZO-1 expression (brown) was continuously and evenly distributed as well as being tightly packed, with smooth edges and a strong positive expression. ZO-1 was unevenly distributed, with rough edges and faded staining in the CLP group. However, in the CLP + emodin group, ZO-1 staining was darker and presented a continuous distribution. Western blotting (Fig. 4D) and RT-qPCR analysis (Fig. 4F) showed that ZO-1 protein expression at 12 h (P<0.05) and mRNA levels at 24 h (P<0.01) were significantly decreased in the CLP group.
compared with the sham group. After emodin intervention, the protein expression levels of ZO-1 were augmented in the emodin pre-treatment groups at 12 and 24 h compared with the CLP treatment alone group, and there was a statistically significant difference ($P<0.01$; 12 and 24 h, respectively). The mRNA levels of ZO-1 were consistent with that of the protein expression ($P<0.05$ and $P<0.01$; 12 and 24 h, respectively). These results indicated that emodin may inhibit the increase in intestinal barrier permeability in sepsis by promoting the expression of ZO-1.

**Emodin partially promotes expression of the intestinal epithelial TJ protein occludin in CLP-induced septic rats.** As depicted in Fig. 4, immunohistochemical microscopy images showed occludin expression in the ileums of septic rats (Fig. 4C). In the sham group, occludin expression (brown) was uniformly distributed in the intestinal epithelial cells at the apex of each connection and tightly packed within smooth edges. Occludin was unevenly distributed, with rough edges and darker colours in the CLP group. However, in the CLP + emodin group, occludin staining was darker and with a continuous distribution. Western blot assays showed that compared with the sham group, there was no obvious change in the expression levels in the CLP group (Fig. 4D). RT-qPCR analysis showed that compared with levels in the sham group, the levels of occludin mRNA were significantly raised in the CLP group at 12 h ($P<0.01$; Fig. 4G). After emodin pre-treatment, the protein levels of occludin were increased in the CLP + emodin group, and there was a significant difference at 12 h ($P<0.01$). However, occludin mRNA was significantly decreased at 12 h and 24 h ($P<0.01$). These data suggested that emodin can inhibit the increase in intestinal barrier permeability in sepsis by promoting the expression of occludin protein.

**Discussion**

The present study confirmed the protective effect of emodin on CLP-induced intestinal epithelial barrier injury in sepsis. It was found that emodin inhibited the increase in intestinal barrier permeability induced by CLP. Emodin may also maintain the integrity of the intestinal epithelial TJ barrier by promoting the expression of TJ proteins, including claudin-3, ZO-1 and occludin. CLP-induced sepsis is the most commonly used animal modelling method for sepsis (28). This model
accurately represents the progression and properties of human sepsis. The model has a haemodynamic and metabolic phase similar to abdominal infections, accompanied by the presence of different stages of inflammation, as well as a prolonged and reduced cytokine release (11).

In the present study, CLP was used to construct a classical model of septic intestinal injury. The results showed that the intestinal mucosa appeared to have different degrees of pathological changes in the CLP group at 12 and 24 h following treatment, including intestinal epithelial inflammatory cell infiltration, intestinal villi that were not aligned and even the occurrence of shedding, all of which were consistent with previous reports (29,30). However, it was found that the intestinal mucosal injury score of the 24 h CLP group was higher than that of the 12 h CLP group, and the pathological changes in the intestinal mucosa were more severe at 24 h. The reason for this phenomenon may be related to the CLP modelling method. With the progression of CLP, the bacteria and toxins in the intestinal cavity invade distant organs and the circulatory system through the portal system, the intestinal lymphatic pathway, and the direct osmotic reabsorption pathway at 24 h (31,32). The liver and lungs receive venous blood and lymph, respectively, from the gastrointestinal tract. Inflammatory effectors are activated by intestinal bacteria and toxins, releasing cytokines and inflammatory mediators, which in turn further stimulates serious systemic inflammation and aggravates intestinal mucosal damage (14). DAO is an important indicator for measuring intestinal mucosal damage, and a reduction in DAO indicates that the integrity of the intestinal mucosa is destroyed (33). Lactulose is a disaccharide with a molecular weight of 342, and mannitol is a monosaccharide with a molecular weight of 182. Both of these sugars are not easily metabolised in the body. Generally, lactulose and mannitol are excreted in the urine and can be accurately quantified. The urine L/M ratio is a classic method for detecting intestinal barrier function and intestinal barrier permeability (34). In the present study, DAO levels and the L/M ratio were examined to evaluate the integrity of the intestinal barrier in sepsis. The results reflected that DAO levels and the L/M ratio were increased in the CLP group at 12 and 24 h. The DAO levels in the 24 h CLP group were markedly higher than those at 12 h. This trend was consistent with the extent of intestinal mucosal damage. These results also indirectly confirmed the hypothesis that intestinal mucosal damage is more severe at 24 h after CLP compared to at 12 h.

Emodin has been shown to reduce septic jejunal damage by inhibiting apoptosis of intestinal epithelial cells through anti-inflammatory effects (35). In the present study, light microscopy and electron microscopy were used to observe the pathological changes in the intestinal mucosal epithelium. The results showed that emodin can significantly reduce the pathological damage to intestinal mucosa and reduce the Chiu's ileal score. Under light microscopy, the intestinal mucosal tissue showed oedema and was infiltrated with inflammatory cells. The structure of intestinal villi was also complete. Electron microscopy showed that the microvilli on the surface of the

![Figure 4. Regulation of intestinal tight junction proteins by emodin in CLP-induced septic rats. Immunohistochemical microscopy images showing the expression of (A) claudin-3, (B) ZO-1 and (C) occludin in the ileums of septic rats. Claudin-3, ZO-1 and occludin (brown) showed intense staining in the sham group ileum tissue nucleus. (blue); however, these proteins were less frequently detected in the CLP group. Moreover, expression was markedly increased in the CLP rats that were treated with emodin. (D) Western blot assays showing that the expression levels of claudin-3, ZO-1 and occludin. Reverse transcription-quantitative PCR analysis showed that the mRNA levels of (E) claudin-3, (F) ZO-1 and (G) occludin in the ileums of septic rats. Data are presented as the mean ± SD. *P<0.05 and **P<0.01 vs. the corresponding CLP group; *P<0.05 and **P<0.01 vs. the corresponding sham group. Red arrows indicate where the expression of tight junction protein is more apparent. Magnification, x200. CLP, cecal ligation and puncture; ZO-1, zonula occludens-1.
intestinal epithelium were neatly arranged, the TJ structures of the epithelial cells were intact, the gaps were narrowed and the junctions were tight. In addition, Chiu's intestinal injury score was also significantly reduced, all of which suggested that emodin can attenuate CLP-induced intestinal epithelial barrier damage in sepsis. The DAO activity and urine L/M ratio are important indicators for the clinical detection of increased permeability of the intestinal wall (36). After emodin pre-treatment, DAO activity in the blood and the L/M ratio in the urine showed a downward trend compared with the CLP treatment group alone, and this trend was more obvious at 24 h. This suggested that emodin may inhibit the increase in intestinal permeability in septic rats and maintain the integrity of the intestinal epithelial TJ barrier.

The intact intestinal epithelial TJ barrier plays a key role in sepsis (37). The barrier can prevent intestinal pathogens from entering the intestinal tract through the paracellular pathway. The integrity of the intestinal epithelial TJ barrier is maintained by an intercellular junction complex formed by TJs, adhesion junctions, desmosomes and gap junctions (38). These ligation complexes form a semi-permeable diffusion barrier between individual cells. They can prevent the abnormal passage of antigens, solutes and water. TJs provide the backbone of the structural integrity of the barrier and also provide a physical basis for the epithelial barrier to ions and solutes (39). TJs are located at the apical ends of the lateral membrane of epithelial cells (40) and have been shown to contain at least 40 proteins (9), such as claudins, ZO-1 and occludin (41). There are two main ways to regulate TJ transport, the pore pathway and the leak pathway (42). The first pathway is characterized by a small pore, which is thought to be created by claudins. The pore pathway is closely related to claudin protein activity (43) and allows the passage of small solutes and the transport of specific ions. Different claudin proteins have different functions. In particular, claudin-3, a barrier-forming protein, has no charge selectivity and is ubiquitously expressed in the jejunum, ileum and colon of rats (44). Previous studies suggested that the permeability of the pore pathway can directly regulate myosin light chain kinase (MLCK) by tumour necrosis factor (TNF-α) (45). When sepsis occurs, TNF-α regulates the upregulation of MLCK promoter activity through the NF-κB signalling pathway, thereby inducing increased expression of MLCK (46). Increased expression of MLCK can further promote increases in the permeability of the pore pathway, which affects the expression of claudin proteins (42). García-Hernández et al. (47), found that claudin-3 was expressed at lower levels in inflammatory bowel disease. Haines et al. (19), found that the protein expression levels of claudin-3 were positively correlated with intestinal epithelial tightness. In the present study, immunohistochemistry, western blotting and RT-qPCR were used to analyse the expression profile of claudin-3 in intestinal tissues. The results showed that the grading grey scales of claudin-3 protein and the mRNA levels of claudin-3 were lower in the CLP group compared with those of the corresponding sham group, with a significant difference at 24 h. The low expression of claudin-3 in the CLP model group is consistent with that of existing research (48). These results indicated that CLP may reduce intestinal barrier integrity by reducing the expression of the barrier-forming protein claudin-3.

The leak pathway controls the paracellular transport of large uncharged solutes (proteins and bacterial LPS but not bacterial cells). Under normal physiological conditions, LPS in the intestinal lumen has no effect on intestinal wall integrity. When sepsis occurs, LPS and inflammatory cytokines (such as TNF-α) in the intestinal lumen can enter the body through the leak pathway (47). ZO-1 and occludin are related to the leak pathway and are both involved in the maintenance and regulation of the leakage channel flux barrier. ZO-1 is critical for the assembly of TJs and epithelial barrier functions. Claudins and occludin proteins are linked to cytoskeletal actomyosin fibres by members of the ZO-1 protein family (49). In addition to providing a bridge between occludin and claudins and the cytoskeleton, ZO-1 may also affect the expression levels of transmembrane proteins at the transcriptional and post-translational levels (50). Occludin, a TJ protein, is mainly located in the TJs of cells after phosphorylation. When occludin is abnormally distributed and expressed in the structure of the small intestine, there is an increase in the intercellular space and an increase in permeability between endothelial cells (31). Zhang et al. (51), found that the expression levels of the intestinal epithelial TJ proteins, ZO-1 and occludin, were both decreased in an LPS-induced sepsis model. In the present study, immunohistochemical staining, western blotting and RT-qPCR were used to detect the expression profile of ZO-1 and occludin in the intestinal epithelial barrier in sepsis. The grey scales of ZO-1 protein showed a downward trend in the CLP group, and there was a significant difference at 12 h. The mRNA levels of ZO-1 significantly decreased in the CLP group at 24 h, but were increased at 12 h. This phenomenon also occurs in different tissues of other animal models (52). The decrease in ZO-1 protein at 12 h could not be explained by a reduction in ZO-1 transcription, which may be a secondary factor to some combination of post-translational regulation or degradation (52). However, occludin protein expression did not change during sepsis, but mRNA levels showed an upward trend. It is possible that occludin protein is modulated via post-transcriptional or post-translational regulations (53).

Decreased expression levels of TJ proteins are strongly associated with impaired intestinal barrier function (54). Thus, the protective effect of emodin against CLP-induced intestinal barrier injury can be partially explained by the increased expression of TJ proteins. In recent years, numerous scientific reports described that emodin has an anti-inflammatory effect and can reduce the expression of the inflammatory factor TNF-α (55-57). Compared with expression in the corresponding CLP group, the protein expression levels of claudin-3 in the CLP + emodin group showed a continuous and uniform distribution, with a smoother edge and an enhanced positive signal. In addition, the protein and mRNA expression levels of claudin-3 were significantly increased in the CLP + emodin group compared with the CLP alone treatment group. It is possible that emodin can reduce TNF-α levels in the sepsis model (58) and further inhibit MLCK activation. Further studies are required to clarify the detailed mechanisms of action. These data indicated that emodin may inhibit the increase in intestinal barrier permeability by promoting the transcription and translation of the TJ protein claudin-3.
The present study also found that in the emodin pre-treatment group, expression of ZO-1 and occludin proteins showed a continuous and uniform distribution, with a smoother edge and an enhanced positive signal, when compared with that of the corresponding CLP group. Moreover, protein and mRNA expression levels of ZO-1 were significantly increased in the CLP + emodin group. However, while the expression of occludin protein was increased, the mRNA was not. Although studies have found that occludin overexpression is protective in Madin-Darby canine kidney cells in vitro (59), in vivo studies indicate that occludin gene defects do not affect the integrity of intestinal epithelial TJs (60). Therefore, further investigation is needed to determine whether occludin plays a role in intestinal epithelial paracellular permeability. Together, these findings suggested that emodin may inhibit the increase in intestinal barrier permeability by promoting the transcription and translation of ZO-1 and occludin proteins, at least to a certain degree.

In conclusion, emodin may alleviate intestinal barrier damage caused by CLP, inhibit the increase in intestinal barrier permeability and maintain the integrity of the intestinal epithelial barrier. Intestinal epithelial TJ proteins are key molecules for the determination of intestinal epithelial barrier permeability. Based on results from previous studies and the present study, it is speculated that the amelioration of intestinal epithelial barrier damage by emodin can be attributed, at least in part, to the promotion of claudin-3, ZO-1 and occludin expression. However, the specific mechanism of action requires further exploration. In the present study, other TJ proteins were not tested, and the effect of emodin on other TJ proteins is not fully understood. Despite these limitations, the protective effect of emodin on CLP-induced intestinal epithelial TJ barrier injury was investigated and an understanding of the protective effect of emodin on regulating intestinal barrier dysfunction in sepsis was provided.

Acknowledgements

Not applicable.

Funding

The present study was supported by funding from the National Natural Science Foundation of China (grant no. 81573901).

Availability of data and material

The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YL, RG and YS designed experiments and analyzed and interpreted data. YL, RG, MZ, PC and JL performed experiments and collected data. YS and RG reviewed articles and contributed reagents and materials. YL wrote the manuscript. All authors read and approved the final manuscript.

Ethics and approval

This study was approved by the Ethics Committee of Putuo Hospital affiliated with Shanghai University of Traditional Chinese Medicine. All animal experiments were in accordance with the Experimental Animal Centre Committee of Putuo Hospital (certification no. SYNK 2018-0032).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315: 801-810, 2016.
2. Condotta SA, Cabrera-Perez J, Badovinac VP and Griffith TS: T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression. Crit Rev Immunol 33: 23-40, 2013.
3. Cao Y, Chen Q, Wang Z, Yu T, Wu J, Jiang X, Jin X and Lu W: PLK1 protects against sepsis-induced intestinal barrier dysfunction. Sci Rep 8: 1055, 2018.
4. Hua S, Liu X, Lu S and Wang Z: Protective effects of curcubitacin B on acute lung injury induced by sepsis in rats. Med Sci Monit 23: 1355-1362, 2017.
5. Liu W, Wang XH, Yang XJ, Zhang XY and Qi WJ: Intestinal barrier dysfunction and its related factors in patients with sepsis. Zhonghua Yi Xue Za Zhi 96: 3568-3572, 2016 (In Chinese).
6. Josep BP, Klingensmith NJ, Liang Z, Breed ER, Burd EM, Mittal R, Dominguez JA, Pietric B, Ford ML and Coopersmith CM: Mechanisms of intestinal barrier dysfunction in sepsis. Shock 46: 52-59, 2016.
7. Xu J, Liu Z, Zhan W, Jiang R, Yang C, Zhan H and Xiong Y: Recombinant TsP53 modulates intestinal epithelial barrier integrity via upregulation of ZO-1 in LPS-induced septic mice. Mol Med Rep 17: 1212-1218, 2018.
8. Lu WH, Jin XJ, Jiang XG, Wang Z, Wu JY and Shen GG: Resuscitation with hydroxyethyl starch 130/0.4 attenuates intestinal injury in a rabbit model of sepsis. Indian J Pharmacol 47: 49-54, 2015.
9. Li Q, Zhang Q, Wang C, Liu X, Li N and Li J: Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol 218: 210-221, 2009.
10. Gu L, Li N, Gong J, Li Q, Zhu W and Li J: Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis 203: 1602-1612, 2011.
11. Wang L, Cui YL, Zhang Z, Lin ZF and Chen DC: Rhubarb monomers protect intestinal mucosal barrier in sepsis via junction proteins. Chin Med J (Engl) 130: 1218-1225, 2017.
12. Li MX, Liu JF, Lu JD, Zhu Y, Kuang DW, Xiang JB, Sun P, Wang W, Xue J, Gu Y, et al: Plasmaadilfiltration ameliorating gut mucosal barrier dysfunction and improving survival in porcine sepsis models. Intensive Care Med Exp 4: 31, 2016.
13. Chen G, Huang B, Fu S, Li B, Ran X, He D, Jiang L, Li Y, Liu B, Xie L, et al: G protein-coupled receptor 109A and host microbiota, oduilate intestinal epithelial integrity during sepsis. Front Immunol 9: 2079, 2018.
14. Chen DC and Wang L: Mechanisms of therapeutic effects of rhubarb on gut origin sepsis. Chin J Traumatol 12: 365-369, 2009.
15. Li P, Lu Q, Jiang W, Pei X, Sun Y, Hao H and Hao K: Pharmacokinetics and pharmacodynamics of rhubarb anthraquinones extract in normal and disease rats. Biomed Pharmacother 91: 425-435, 2017.
16. Wang G, Sun B, Zhu H, Gao Y, Li X, Xue D and Jiang H: Protective effects of emodin combined with dan-shen-su on experimental severe acute pancreatitis. Inflamm Res 59: 479-488, 2010.

17. Gao M, Jiang J, Zhang H, Xiao Y, Kao X, Liu Y and Liu Z: Anti-inflammatory effects of emodin on lipopolysaccharide-induced keratitis in Wistar rats. Int J Clin Exp Med 8: 12382-12389, 2015.

18. Ning JW, Zhang Y, Yu MS, Gu ML, Xu J, Usman A and Ji F: Emodin alleviates intestinal mucosal injury in rats with severe acute endotoxin shock. Hepatobiliary Pancreat Dis Int, 17(6): p. 431-436.

19. Haines RJ, Beard RS Jr, Chen L, Eitnier RA and Wu MH: Interleukin-1beta mediates beta-catenin-driven downregulation of claudin-3 and barrier dysfunction in Caco2 cells. Dig Dis Sci, 61(10): 2322-2331, 2016.

20. Holmes JL, Van Itallie CM, Rasmussen JE and Anderson JM: Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. Gene Expr Patterns 6: 581-588, 2006.

21. Rahmer C, Mitic LL and Anderson JM: Heterogeneity in expression and subcellular localization of claudins 2, 5, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 120: 411-422, 2001.

22. Sun Y, Sun L, Liu S, Song J, Cheng J and Liu J: Effect of emodin on Aquaporin 5 expression in rats with sepsis-induced acute lung injury. J Tradit Chin Med 35: 679-684, 2015.

23. Perich P, Benech-Camblor M, Alcoverro SA, Castilhos LG, Silveira KL, Rezer JF, Doleshi PH, Abdalla FH, Santos KS, Leal CAM, et al: Sepsis induced by cecal ligation and perforation (CLP) alters nucleotidase activities in platelets of rats. Microbiol Pathog 111: 345-351, 2017.

24. Shi Z, Zhang R, Zhang H and Zeng S: Effect of triggering receptor expressed on myeloid cells 1 (TREM-1) blockade in rats with cecal ligation and puncture (CLP)-induced sepsis. Med Sci Monit 23: 5049-5055, 2017.

25. Wu J, Lyu B, Gan T, Wang L and Zhu M: Electroacupuncture improves acute bowel injury recovery in rat models. Exp Ther Med 14: 4665-4667, 2017.

26. Guo S, Nighton M, Al-Sadi R, Alhmoud T, Nighton P and Ma TY: Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J Immunol 195: 4999-5010, 2015.

27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

28. Zhang B, Liu C, Yang N and Wang X: A comparative study of changes of autophagy in rat models of CLP versus LPS induced sepsis. Exp Ther Med 14: 2194-2200, 2017.

29. Gao M, Jiang Y, Xiao X, Peng Y, Xiao X and Yang M: Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. J Surg Res 195: 550-558, 2015.

30. Zhou H, Liang H, Li ZF, Xiang H, Liu W and Li JG: Vagus nerve stimulation improves intestinal tight junction disruption in endotoxemic mice through α7 nicotinic acetylcholine receptors. Shock 40: 144-151, 2013.

31. Yang J, Zhang J, Wu U, Zhang J, Dong J, Guo P, Tang S, Zhang W and Wu F: Iminopem and normal saline with cyclophosphamide improve acute bowel injury recovery in rat models. Exp Ther Med 19: 3287-3292, 2019.

32. Garcia-Hernandez V, Quiros M and Nusrat A: Intestinal epithelial Claudins: Expression and regulation in homeostasis and inflammation. Ann N Y Acad Sci 1397: 66-79, 2017.

33. Xing X, Jiang R, Wang L, Lei S, Zhi Y, Wu Y, Zhu M, Huang L, Xia G and Chen Z: Shengfu injection alleviates intestine epithelial damage in septic rats. Am J Emerg Med 33: 1665-1670, 2015.

34. Sonika U, Goswami P, Thakur B, Yadav R, Das P, Ahuja V and Saraya A: Mechanism of increased intestinal permeability in acute pancreatitis: Alteration in tight junction proteins. J Clin Gastroenterol 51: 461-466, 2017.

35. Li W, Sun K, Ji Y, Wu Z, Wang W, Dai Z and Wu G: Glycine regulates expression and distribution of claudin-7 and ZO-3 proteins in intestinal porcine epithelial cells. J Nutr 146: 964-969, 2016.

36. Zhang S, Zheng S, Wang X, Shi Q, Wang X, Yuan S, Wang G and Ji Z: Carbon monoxide-releasing molecule-2 reduces intestinal epithelial tight-junction damage and mortality in septic rats. PLoS One 10: e0145988, 2015.

37. Eadon MT, Hack BK, Xu C, Ko B, Toback FG and Cunningham PN: Endotoxemia alters tight junction gene and protein expression in the kidney. Am J Physiol Renal Physiol 303: F821-F830, 2012.

38. Wang J, An BS, Yang HL and Dong Y: Tissue-specific expression of occludin, zona occludens-1, and junction adhesion molecule A in the duodenum, ileum, colon, kidney, liver, lung, and skeletal muscle of C57BL mice. J Physiol Pharmacol 64: 11-18, 2013.

39. Yan H and Ajawon KM: Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PLoS One 12: e0179856, 2017.

40. Chen D, Liu J, Lu L, Huang Y, Wang Y, Wang M, Liu Y, Xie D, Chen J, Diao et al: Emodin attenuates TNF-α-induced apoptosis and autophagy in mouse C2C12 myoblasts through the phosphor-inositol-3’-kinase/Akt/mammalian target of rapamycin/4E-BP pathway. J Cell Physiol 232: 1202-1209, 2017.

41. Xia S, Ni Y, Zhou Q, Liu H, Xiang H, Sui H and Shang D: Emodin attenuates severe acute pancreatitis via antioxidant and anti-inflammatory activity. Inflammation 42: 2129-2138, 2019.

42. Dong Y, Zhang L, Jiang Y, Dai J, Tang L and Liu Q: Emodin reactivated autophagy and alleviated inflammatory lung injury in mice with lethal endotoxemia. Exp Anim 68: 569-571, 2019.

43. Xia XM, Li BK, Xing SM and Ruan HL: Emodin promoted pancreatic claudin-5 and occludin expression in experimental acute pancreatitis rats. World J Gastroenterol 18: 2312-2319, 2012.

44. Cummins PM: Occludin: One protein, many forms. Mol Cell Biol 32: 242-250, 2012.

45. Van Itallie CM and Anderson JM: Claudin interactions in and along the gastrointestinal tract reveals complex expression patterns. Gene Expr Patterns 6: 581-588, 2006.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.